Table 1 Characteristics of 312 patients with hematological malignancies who received our modified regimen.
Characteristics (n = 312) | |
|---|---|
Age in yr, median (range) of the recipient | 32 (3–60) |
Gender, no(%) | |
Male | 156(50.0) |
Female | 156(50.0) |
Disease status | |
Acute myeloid leukemia (AML), no(%) | 180(57.7) |
CR1/CR > 1/Not in CR1 | 163/11/6 |
Acute lymphoid leukemia (ALL), no(%) | 102(32.7) |
Ph-negative B-ALL, no(%) | 25(8.0) |
CR1/CR > 1/Not in CR1 | 20/4/1 |
Ph-positive B-ALL, no(%) | 59(18.9) |
CR1/CR > 1/Not in CR1 | 53/4/2 |
T-ALL, no(%) | 18(5.8) |
CR1/CR > 1/Not in CR1 | 17/1/0 |
Myelodysplastic syndrome (MDS), no(%) | 16(5.1) |
Low risk/high risk | 2/14 |
Chronic myelogenous leukemia (CML), no(%) | 8(2.6) |
Hybrid acute leukemia (HAL), no(%) | 6(1.9) |
CR1/CR > 1/Not in CR1 | 6/0/0 |
